Células CAR-T y Células-Tronco: Sinergia Terapêutica e Revolução na Medicina Regenerativa
DOI:
https://doi.org/10.19123/REixo.v15.n2.13Palabras clave:
Autoinmunes, Cánceres hematológicos., Ingeniería genética, inmunoterapia, Tumores sólidos.Resumen
En las últimas décadas la terapia celular ha demostrado numerosos avances, entre ellos se destaca la inmunoterapia das CAR-T juntamente con células troncales en diferentes áreas, por ejemplo: neoplasias, enfermedades autoinmunes y enfermedades crónicas infecciosas como el VIH/SIDA. Su capacidad sinérgica emerge como una alternativa de intervención para patologías refractarias en relaciones a tratamientos convencionais abriendo espacio para una gama de nuevas posibilidades. Devido a esto, este artículo tem como objetivo evidenciar a través de una revisión literaria de los aspectos prácticos de la utilización de las células CAR-T, como posibilidades de aplicación en conjunto de estas con células-tronco y su potencial en terapia celular. Para este estudio foram realizado buscas nas siguientes bases de datos: PubMed, Scielo e ScienceDirect, utilizados os descritores “Car-t cell and mesenchymal stem cell”; “Células madre mesenquimales y cart-t”; “Células autoinmunes y madre; VIH y CAR-T junto con células madre”; “Aplicabilidad de las células car-t en células madre mesenquimales”. Los artículos presentan beneficios en la relación con el uso de células troncales con CAR-T a partir de una mejor capacidad antitumoral y aún proporcionan una defensa imunológica natural del organismo. Apesar esto, algunas limitaciones y vistas como baja persistencia y alto costo de producción, fazendo-se necessários mais estudios sobre un tema e inversiones para establecer su aplicación terapéutica.
Referencias
ANDO, Makoto et al. (2021) Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory–Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand. Cancer Research Communications, v. 1, n. 1, p. 41-55.
ARAÚJO, D. F. B. et al. (2020) Hematological and biochemical toxicity analysis of chemotherapy in women diagnosed with cervical cancer. Jornal brasileiro de patologia e medicina laboratorial.
AJINA, A.; MAHER, J. (2019) Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. Em: Progress in Molecular Biology and Translational Science. Elsevier. p. 217–292.
BAKER, Daniel J.; JUNE, Carl H. (2022) CAR T therapy extends its reach to autoimmune diseases. Cell, v. 185, n. 24, p. 4471-4473. Disponível em: https://doi.org/10.1016/j.cell.2022.10.026.
BARBER-AXTHELM, Isaac M. et al. (2021) Stem cell–derived CAR T cells traffic to HIV reservoirs in macaques. JCI Insight, v. 6, n. 1. Disponível em: https://doi.org/10.1172/jci.insight.141502.
CARVALHO, Luiz Felipe Chaves; RODRIGUES, Fabiano de Abreu Agrela. (2023) Uso de células-tronco no tratamento dos atletas. Cuadernos de Educación y Desarrollo, v. 15, n. 8, p. 7395-7406.
CONCEICAO, L. C. et al. (2020) Coleta Por aférese: Um relato de experiência. Hematology, transfusion and cell therapy, v. 42, p. 334.
CHAN, L. Y. et al. (2022) CAR-T cells/-NK cells in cancer immunotherapy and the potential of MSC to enhance its efficacy: A review. Biomedicines, v. 10, n. 4, p. 804.
CHEN T, Deng J, Zhang Y, Liu B, Liu R, Zhu Y, Zhou M, Lin Y, Xia B, Lin K, Ma X, Zhang H. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Mol Cancer. 2024 Mar 11;23(1):53. doi: 10.1186/s12943-024-01938-8. PMID: 38468291; PMCID: PMC10926606.
CHEN, Y.-J.; ABILA, B.; MOSTAFA KAMEL, Y. (2023) CAR-T: What is next? Cancers, v. 15, n. 3, p. 663.
CHEN, Zhuo; XIA, Xue Wei; YAO, Mengwei; YANG, Yi; AO, Xiang; ZHANG, Zhaoqi; GUO, Li; XU, Xiang. (2024) The dual role of mesenchymal stem cells in apoptosis regulation. Morte Celular e Doença, v. 15, n. 250. DOI: https://doi.org/10.1038/s41419-024-06620-x.
DAI, H. et al. (2020) Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of hematology & oncology, v. 13, n. 1.
FÉLIX, O. et al. (2023) Experiência no transplante autólogo de células-tronco hematopoéticas periféricas em pacientes com peso igual ou inferior a 25 kg. Hematology, transfusion and cell therapy, v. 45, p. S512–S513.
FINCK, A.; GILL, S. I.; JUNE, C. H. (2020) Cancer immunotherapy comes of age and looks for maturity. Nature Communications, v. 11, n. 1.
GILL, S.; MAUS, M. V.; PORTER, D. L. (2016) Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Reviews, v. 30, n. 3, p. 157–167.
HARRISON, R. P. et al. (2019) Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy, v. 21, n. 2, p. 224–233.
HIRAYAMA, A. V. et al. (2019) High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, v. 134, n. 7, p. 636–640.
HUANG, Shengkang et al. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Molecular Cancer, v. 22, n. 1, 6 maio 2023.
JUNE, C.H. et al. (2018) CAR T Cell Immunotherapy for Human Cancer. Science, v. 359, n. 6382, p. 1361-1365. Disponível em: https://doi.org/10.1126/science.aao1485.
KIM, S.; MOON, E. K. (2017) Development of novel avenues to overcome challenges facing CAR T cells. Translational research: the journal of laboratory and clinical medicine, v. 187, p. 22–31.
LI, M. et al. (2017) Application of induced pluripotent stem cell technology to the study of hematological diseases. Cells (Basel, Switzerland), v. 6, n. 1, p. 7
LESCH, S. et al. (2020) Determinants of response and resistance to CAR T cell therapy. Seminars in cancer biology, v. 65, p. 80–90.
LEE, Y.-H.; KIM, C. H. (2019) Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Archives of pharmacal research, v. 42, n. 7, p. 607–616.
MADEIRA, M. R. C.; MARADEI, S. C. (2023) A incidência da síndrome de liberação de citocinas nos transplantes de células-Tronco hematopoéticas haploidêntico: Um estudo retrospectivo no instituto Nacional de Câncer do Rio de Janeiro. Hematology, transfusion and cell therapy, v. 45, p. S546.
MACKENSEN, Andreas et al. (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine. Disponível em: https://doi.org/10.1038/s41591-022-02017-5.
MAJZNER, R. G.; MACKALL, C. L. (2018) Tumor antigen escape from CAR T-cell therapy. Cancer discovery, v. 8, n. 10, p. 1219–1226.
MICHELOZZI, Ilaria M.; KIRTSIOS, Efstratios; GIUSTACCHINI, Alice. (2021) Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. Cancers, v. 13, n. 11, p. 2816.
MITRA, A. et al. (2023) From bench to bedside: the history and progress of CAR T cell therapy. From bench to bedside: the history and progress of CAR T cell therapy, v. 14, n. 1188049.
MORRIS, E. C. et al. (2021) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, v. 22.
MÜLLER, F. et al. (2024) CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up. The New England journal of medicine, v. 390, n. 8, p. 687–700.
NEELAPU, S.S. et al. (2018) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, v. 379, n. 26, p. 2537-2548. Disponível em: https://doi.org/10.1056/NEJMoa1804980.
PEDRO JÚNIOR, J. et al. (2023) Update on the use of immunotherapy in the treatment of Cancer. Brazilian Journal of Health Review, v. 6, n. 3, p. 12101–12114.
PEREIRA, L. DA V. (2008) The importance of the use of stem cells for public health. Ciência & saúde coletiva, v. 13, n. 1, p. 07–14.
RAMOS, R. N. et al. (2021) Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. Hematology, transfusion and cell therapy, v. 43 Suppl 2, p. S46–S53.
RIET, Tobias; CHMIELEWSKI, Markus. (2022) Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges. Frontiers in Immunology, v. 13. Disponível em: https://doi.org/10.3389/fimmu.2022.934343.
ROCHA, A. S.; MAIA, L.; GUASTALI, M. D.; VOLPATO, R.; ALVARENGA, F. da C. L. e. (2023) Considerações sobre células-tronco embrionárias. Veterinária e Zootecnia, Botucatu, v. 19, n. 3, p. 303–313. Disponível em: https://rvz.emnuvens.com.br/rvz/article/view/1408. Acesso em: 16 jun. 2024
RODRIGUEZ, M. et al. (2023) Mesenchymal Stem Cells Potentiate CAR-T Cell Persistence and Antitumor Activity Through Paracrine Signaling Modulation. Molecular Therapy, v. 31, n. 5, p. 1150-1161. Disponível em: https://doi.org/10.1016/j.molther.2023.03.015.
RUIZ, M. A.; BYDLOWSKI, S. P.; SEBER, A. (2009) Cell therapy is a medicine of the future? Revista brasileira de hematologia e hemoterapia, v. 31.
SALGADO, M. (2023) CAR-T cell therapy for HIV cure. Viruses, v. 15, n. 9, p. 1793.
SAMI, A. (2023) Next generation stem cells and their implications in cancer therapy. JPMA. The Journal of the Pakistan Medical Association, v. 73, n. 2, p. S98–S104,.
SANBER, K.; JOSEPH, S. K.; AHMED, N. (2020) CAR T-cell therapy for CNS malignancies. Em: Chimeric Antigen Receptor T-Cell Therapies for Cancer. Elsevier. p. 165–198.
SEBER, A. et al. (2021) Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. Hematology, transfusion and cell therapy, v. 43 Suppl 2, p. S13–S21.
SHI, M. et al. (2024) Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications, v. 15, n. 1, p. 3371.
SHI, Y. et al. (2025) Engineered mesenchymal stem/stromal cells against cancer. Cell Death and Disease, v. 16, n. 1.
SILVA, F. M. et al. (2024) Tratamento oncológico com células CAR-T: remissão total do câncer de próstata através da terapia celular. Revista JRG de Estudos Acadêmicos, v. 7, n. 15, p. 41-55. Disponível em: https://doi.org/10.55892/jrg.v7i15.1454.
SILVEIRA, F. M. et al. (2021) Impacto do tratamento quimioterápico na qualidade de vida de pacientes oncológicos. Acta Paulista de Enfermagem, v. 34.
SOLANO, C. et al. (2023) Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ open, v. 13, n. 7, p. e071371.
SOARES, J. E. P. et al. (2022) CAR-T cell therapy: cell reprogramming to combat malignant neoplasms. Revista Médica de Minas Gerais, v. 32.
SMITH, J. et al. (2024) Enhancement of CAR-T Cell Efficacy by Mesenchymal Stem Cell-Derived Extracellular Vesicles in Solid Tumors. Journal of Experimental & Clinical Cancer Research, v. 43, n. 2, p. 180-195. Disponível em: https://doi.org/10.1186/s13046-024-0180.
SPERONI, A. V.; MENEZES, R. A. (2014) Terapia Celular: as promessas das “células da esperança”. In: 29ª Reunião Brasileira de Antropologia, 2014, Natal/RN. ANAIS DA 29ªRBA.
STERNER, R. C., & STERNER, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4), 69. https://doi.org/10.1038/s41408-021-00459-7.
SUN, D. et al. (2024) CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review). Molecular medicine reports, v. 29, n. 3.
TIAN, Z.-Y. et al. (2023) Introduction to stem cells. Progress in Molecular Biology and Translational Science, v. 199, p. 3–32.
TOKAREW, N. et al. (2018) Teaching an old dog new tricks: next-generation CAR T cells. British Journal of Cancer, v. 120, n. 1, p. 26–37.
TROUNSON, A.; MCDONALD, C. (2015) Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell, v. 17, n. 1, p. 11–22.
XU, J. et al. (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. Journal of hematology & oncology, v. 17, n. 1, p. 23.
YAN, L., LI, J., & ZHANG, C. (2023). The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Communication and Signaling: CCS, 21(1), 187. https://doi.org/10.1186/s12964-023-01191-4.
ZAKRZEWSKI, W. et al. (2019) Stem cells: past, present, and future. Stem Cell Research & Therapy, v. 10, n. 1.
ZHANG, Y.; ZHANG, Z. (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology, v. 17, n. 8, p. 1–15.
ZHANG, R., LIU, Q., ZHOU, S., HE, H., ZHAO, M., & MA, W. (2023) Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1. eLife, 12. https://doi.org/10.7554/eLife.82934.
ZHANG, L., TIAN, L., DAI, X. et al. (2020) Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol 13, 153 . https://doi.org/10.1186/s13045-020-00983-2.
Descargas
Publicado
Declaración de disponibilidad de datos
O artigo foi construído de forma coletiva por todos autores.
Número
Sección
Categorías
Cómo citar
Licencia
Derechos de autor 2026 Victória Alferis Lima, Maria Vitória da Silva Xavier, Mariza Brandão Palma, Anísio Francisco Soares (Autor)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Nos seguintes termos:
- Atribuição - Você deve dar o crédito apropriado , fornecer um link para a licença e indicar se as alterações foram feitas . Você pode fazê-lo de qualquer maneira razoável, mas não de qualquer forma que sugira que o licenciante endossa você ou seu uso.
- Não Comercial - Você não pode usar o material para fins comerciais .
- ShareAlike - Se você remixar, transformar ou construir sobre o material, você deve distribuir suas contribuições sob a mesma licença que o original.
- Sem restrições adicionais - Você não pode aplicar termos legais ou medidas tecnológicas que restrinjam legalmente outros de fazer qualquer coisa que a licença permita.
